ISSN 2766-7820

Clinical Image

Open Access, Volume 6

Eosinophilic granulomatosis with polyangiitis: A unique case of secondary medium vessel vasculitis and temporal arteritis

Renee Morecroft¹; Jordan Phillipps²; Jason Sluzevich²; Sehreen Mumtaz^{3*}

¹Department of Internal Medicine, HCA Orange Park, Jacksonville, FL, 32073, USA.

*Corresponding Author: Sehreen Mumtaz, MD

Department of Rheumatology, Mayo Clinic,

Jacksonville, FL, 32224, USA.

Tel: 904-953-2062, Fax: 904-953-0665; Email: mumtaz.sehreen@mayo.edu

Received: Jun 17, 2025
Accepted: Jul 15, 2025
Published: Jul 22, 2025
Archived: www.jcimcr.org
Copyright: © Mumtaz S (2025).

DOI: www.doi.org/10.52768/2766-7820/3697

Keywords: Eosinophilic granulomatosis with polyangiitis; EPGA; Hyper-eosinophilic syndrome-lymphocytic variant;

Rheumatology; Case; Clinical images.

Description

A 60-year-old male presented with a 1-month history of ocular photosensitivity, pruritus, infraorbital swelling, and acute binocular vision loss. He was admitted for evaluation of anterior optic neuropathy and temporal arteritis. Neuro-Ophthalmology recommended 1 g methylprednisolone, leading to significant improvement in right eye vision but persistent left eye deficits. Laboratory tests showed elevated CRP (185.9 mg/L), ESR (128 mm/hr), rheumatoid factor (61 IU/mL), and eosinophilia (absolute 3.06 x 10⁹/L). CT Head and MRI revealed ethmoid cell opacification, soft tissue stranding, and diffuse paranasal sinus mucosal thickening. CT chest revealed pulmonary nodules (Figure 1A; blue arrows denoting lung nodules), ground-glass opacities, and cervical lymphadenopathy. Temporal artery ultrasound (patient declined biopsy) showed decreased compressibility, and a halo sign around the left temporal artery, concerning for giant cell arteritis (Figure 1B and 1C) [1]. He was started on Tocilizumab.

During hospitalization, he developed a purpuric lower extremity rash (Figure 1D and 1E; orange arrows denoting rash)—biopsy confirmed medium vessel vasculitis (Figure 1F). He was started on cyclophosphamide induction therapy and a prednisone taper, on which he had symptomatic and radiographic improvement post discharge.

(Figure 1G), though eosinophilia persisted (absolute 1.02 x 10^9 /L, previously 1.08 x 10^9 /L). Work-up for hyper-eosinophilic malignancy (Leukemia/lymphoma immunophenotyping, T-cell rearrangement, chronic eosinophilia panel) was negative. Following the 3rd dose of cyclophosphamide, he experienced symptom relapse and was started on mepolizumab with improvement. Based on the ACR/EULAR criteria, he scored 10 points due to eosinophilia $\geq 1 \times 10^9$ /L, obstructive lung disease of pulmonary function testing, and extravascular eosinophilic predominant inflammation seen on his skin biopsy [2].

²Department of Dermatology, Mayo Clinic, Jacksonville, FL, 32224, USA.

³Department of Rheumatology, Mayo Clinic, Jacksonville, FL, 32224, USA.

Citation: Morecroft R, Phillipps J, Sluzevich J, Mumtaz S. Eosinophilic granulomatosis with polyangiitis: a unique case of secondary medium vessel vasculitis and temporal arteritis. J Clin Images Med Case Rep. 2025; 6(6): 2810




Figure 1: Clinical image.

Ethics: Written informed consent was obtained for publication. IRB approval/waiving was not required per Mayo Clinic policy given that the study is based on a single patient.

References

- Arida A, Kyprianou M, Kanakis M, Sfikakis PP. The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: a second meta-analysis. BMC Musculoskelet Disord. 2010; 11: 44. doi: 10.1186/1471-2474-11-44. PMID: 20210989; PMCID: PMC2837862.
- Grayson PC, Ponte C, Suppiah R, Robson JC, Craven A, Judge A, et al. DCVAS Study Group. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. Ann Rheum Dis. 2022; 81(3): 309-314. doi: 10.1136/annrheumdis-2021-221794. Epub 2022 Feb 2. PMID: 35110334.

www.jcimcr.org Page 2